Do Naranjo Criteria Still Apply to Ipilimumab-induced Uveitis?

Klin Monbl Augenheilkd 2016; 233(04): 356
DOI: 10.1055/s-0042-104249

Editorial

Georg Thieme Verlag KG Stuttgart · New York

Kann man die Naranjo-Kriterien in Bezug auf die Ipilimumab-induzierte Uveitis immer noch anwenden?

Yan Guex-Crosier

Jules Gonin Eye Hospital, FAA, University of Lausanne, Switzerland

References
1 Naranjo CA, Fornazzari L, Sellers EM. Clinical detection and assessment of drug induced neurotoxicity. Prog Neuropsychopharmacol 1981; 5: 427-434
2 Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691-2697
3 Moorthy RS, Valluri S, Jampol LM. Drug-induced uveitis. Surv Ophthalmol 1998; 42: 557-570